Evidence map›Paper›PMID 37751983›Full record

ArticleBMJ case reports2023

Refractory pembrolizumab immunotherapy-related colitis requiring biological therapy in an inactive HBcAb carrier.

Nidaa Rasheed, Rajan Anand, Mark Maddox, Candice Reyes

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Nidaa RasheedInternal Medicine, University of California San Francisco, Fresno, California, USA nidaa.rasheed@ucsf.edu.
Rajan AnandDepartment of Gastroenterology, University of California San Francisco Fresno, Fresno, California, USA.
Mark MaddoxDepartment of Medical Oncology, Duke University Medical Center, Durham, North Carolina, USA.
Candice ReyesDepartment of Rheumatology, University of California San Francisco, Fresno, California, USA.
University of California, San Francisco · USDuke Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitors are a class of cancer immunotherapy, with a constellation of side effects that require early recognition and management. We present a patient with metastatic adenocarcinoma started on pembrolizumab a month prior, who was admitted to the hospital for bloody diarrhoea. He underwent flexible sigmoidoscopy with biopsy proven grade 3 immune-mediated diarrhoea and colitis. He developed progressively worsening diarrhoea despite appropriate intravenous corticosteroids therapy, and initiation of corticosteroid-sparing therapy was complicated by discovery of hepatitis B core antibodies indicating a chronic hepatitis B carrier state. We discuss our work-up of new onset haemorrhagic diarrhoea in a patient on immunotherapy for metastatic non-small cell lung cancer, as well as a review of current guidelines for antiviral prophylaxis in these patients.

Indexed as

Carcinoma, Non-Small-Cell LungColitisLung NeoplasmsAgedAntibodies, Monoclonal, HumanizedDiarrheaHumansImmunotherapyMaleAntibodies, Monoclonal, HumanizedpembrolizumabGastrointestinal systemGI bleedingHepatitis BMalignant disease and immunosuppression

Identifiers

PMID37751983
PMCPMC10533673
OpenAlexW4387063723

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.